Status:
TERMINATED
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study
Lead Sponsor:
The George Institute
Collaborating Sponsors:
University of Sydney
Conditions:
Stroke
Cerebral Small Vessel Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
TRIDENT Main Study: TRIDENT is a multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial of a fixed low-dose combination BP-lowering pill ("Triple ...
Detailed Description
Intracerebral haemorrhage (ICH) is the most serious type of stroke, accounting for 10% of stroke in high-income countries and up to 50% in low-to-middle income countries, especially in Asia where hype...
Eligibility Criteria
Inclusion
- Eligible for, randomised and continuing in TRIDENT Main Study
- No contraindications to MRI scan of the brain
- Provide informed consent for the MRI Sub-Study
Exclusion
- Any MRI contraindications (e.g. metallic implants, claustrophobia, etc.)
- Less than 6 weeks or greater than 6 months post-randomisation (however, where possible the baseline MRI Sub-Study scan should be conducted as soon as possible after the qualifying ICH. e.g. if the qualifying ICH was 4 months prior to randomisation, the baseline scan should be done as close to 6 weeks post-randomisation as possible)
Key Trial Info
Start Date :
August 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 21 2021
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03783754
Start Date
August 9 2018
End Date
March 21 2021
Last Update
May 25 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Liverpool Hospital
Liverpool, New South Wales, Australia, 2170
2
Sunshine Coast University Hospital
Birtinya, Queensland, Australia, 4575
3
Royal Melbourne Hospital
Melbourne, Victoria, Australia, 3050